Viking Therapeutics Inc. Common Stock (VKTX)
Stock · NASDAQ · Health Care
$25.17as of 10/16/2026
Price chart
Active signals
VKTX Signal Track Record
How signals performed across all stocks →What VKTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -2.4% | 45% | September 15, 2026 |
| Bollinger Band Breakout | 25 | +7.2% | 52% | September 22, 2026 |
| Bollinger Band Breakdown | 22 | +3.0% | 55% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +4.0% | 56% | September 28, 2026 |
| Any 20-session window (baseline) | +0.8% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 65
- Website
- vikingtherapeutics.com/
Fundamentals
- 1-day range
- $27.19$28.2
- Market cap
- $3.88B
- P/E (trailing)
- —
- P/E (forward)
- -6.19
- EPS (trailing)
- $-4.66
- Dividend yield
- —
- Beta
- 0.67
- Avg. volume
- 4.18M
Forecasts
19 analyst ratings
Viking Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VKTXViking Therapeutics Inc. Common Stock$25.17▼ 8.04%Market cap $3.88BP/E —$25.77$43.15
- GMABGenmab A/S ADS$37▼ 2.17%Market cap $3.83BP/E 26.41$1,512$2,369
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- TNGXTango Therapeutics Inc.$22.04▼ 2.91%Market cap $4.19BP/E —$6.69$34.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VKTX Viking Therapeutics Inc. Common Stock | $3.88B | — | $25.17 | ▼ 8.04% | $25.77$43.15 |
| GMAB Genmab A/S ADS | $3.83B | 26.41 | $37 | ▼ 2.17% | $1,512$2,369 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| TNGX Tango Therapeutics Inc. | $4.19B | — | $22.04 | ▼ 2.91% | $6.69$34.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy?Yahoo · 10/2/2026
- Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?Yahoo · 10/2/2026
- LLY Highlights New Efficacy Data From Foundayo and EloraTZP StudiesYahoo · 10/2/2026
- Prediction: This Stock Could Double Over the Next 5 YearsYahoo · 10/2/2026
- Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for InvestorsYahoo · 10/1/2026
- Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to BuyYahoo · 9/30/2026
- Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.Yahoo · 9/30/2026
- Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key FactsYahoo · 9/30/2026
Insider Activity
Insider Actions →- Dorothy Elizabeth Kelly-Gemmell · August 1, 2026 · Grant40.8K
- Dorothy Elizabeth Kelly-Gemmell · August 1, 2026 · Grant6.3K
- Marianna Mancini · July 29, 2026 · Sale18.2K @ $33.47
- Greg Zante · July 29, 2026 · Sale21.2K @ $33.47
- Brian Lian · July 29, 2026 · Sale148.5K @ $33.32
- Brian Lian · July 28, 2026 · Grant221.7K
- Marianna Mancini · July 28, 2026 · Grant31.7K
- Greg Zante · July 28, 2026 · Grant31.7K
- Chen Hubert C · June 1, 2026 · Grant190.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 75.29M
- Total value held
- $2.48B
- Institutional holders
- 403
- Unknown6.88M
- Unknown6.02M
- Unknown5.01M
- Unknown4.82M
- Unknown4.43M
- Unknown4.40M
- Unknown3.01M
- Unknown2.62M
- Unknown2.08M
- Unknown2.08M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Viking Therapeutics Launches New Oral Obesity Study
Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.
Viking Therapeutics Launches New Oral Obesity Study. Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.